Elsilimomab

• CAT Number: I042425
• CAS Number: 468715-71-1
• Purity: ≥95%

Elsilimomab (Cat No.: I042425) is a murine (mouse-derived) monoclonal antibody that targets interleukin-6 (IL-6), a pro-inflammatory cytokine involved in immune responses, inflammation, and cancer progression. By neutralizing IL-6 activity, elsilimomab has shown potential in reducing inflammatory signaling and tumor growth in preclinical studies. It has been explored for treating conditions such as autoimmune diseases and certain cancers where IL-6 plays a pathogenic role. Elsilimomab has also served as a precursor to fully human IL-6 antibodies used in clinical therapies today.

Reference

[1]. Lee JJ, et al. A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer. Mol Ther. 2014 Jul;22(7):1254-1265.
[Content Brief]

[2]. Burger R, et al. Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth. Haematologica. 2017 Feb;102(2):381-390.
[Content Brief]

[3]. Finch DK, et al. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol. 2011 Aug 26;411(4):791-807.
[Content Brief]